Advertisement

Study Findings on Novel Agents in Neoplastic Hematology

The last of four studies featured in this article details results from a single-center phase I trial with idasanutlin, an MDM2 inhibitor, in patients with high-risk polycythemia vera and essential thrombocythemia without prior JAK2 inhibitor therapy. The study shows tolerability and improvement in total symptom score. Multicenter phase II trials in patients with hydroxyurea-resistant disease are underway.

 The ASCO Post